263 related articles for article (PubMed ID: 21062986)
1. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.
Rizvi I; Celli JP; Evans CL; Abu-Yousif AO; Muzikansky A; Pogue BW; Finkelstein D; Hasan T
Cancer Res; 2010 Nov; 70(22):9319-28. PubMed ID: 21062986
[TBL] [Abstract][Full Text] [Related]
2. Verteporfin mediated sequence dependent combination therapy against ovarian cancer cell line.
Erdem SS; Obeidin VA; Yigitbasi T; Tumer SS; Yigit P
J Photochem Photobiol B; 2018 Jun; 183():266-274. PubMed ID: 29747146
[TBL] [Abstract][Full Text] [Related]
3. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
del Carmen MG; Rizvi I; Chang Y; Moor AC; Oliva E; Sherwood M; Pogue B; Hasan T
J Natl Cancer Inst; 2005 Oct; 97(20):1516-24. PubMed ID: 16234565
[TBL] [Abstract][Full Text] [Related]
4. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
5. Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model.
Celli JP; Rizvi I; Evans CL; Abu-Yousif AO; Hasan T
J Biomed Opt; 2010; 15(5):051603. PubMed ID: 21054077
[TBL] [Abstract][Full Text] [Related]
6. In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring.
Zhong W; Celli JP; Rizvi I; Mai Z; Spring BQ; Yun SH; Hasan T
Br J Cancer; 2009 Dec; 101(12):2015-22. PubMed ID: 19920823
[TBL] [Abstract][Full Text] [Related]
7. PDT dose parameters impact tumoricidal durability and cell death pathways in a 3D ovarian cancer model.
Rizvi I; Anbil S; Alagic N; Celli J; Zheng LZ; Palanisami A; Glidden MD; Pogue BW; Hasan T
Photochem Photobiol; 2013; 89(4):942-52. PubMed ID: 23442192
[TBL] [Abstract][Full Text] [Related]
8. Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT.
Evans CL; Abu-Yousif AO; Park YJ; Klein OJ; Celli JP; Rizvi I; Zheng X; Hasan T
PLoS One; 2011; 6(8):e23434. PubMed ID: 21876751
[TBL] [Abstract][Full Text] [Related]
9. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal, label-free, quantitative tracking of cell death and viability in a 3D tumor model with OCT.
Jung Y; Klein OJ; Wang H; Evans CL
Sci Rep; 2016 Jun; 6():27017. PubMed ID: 27248849
[TBL] [Abstract][Full Text] [Related]
11. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells.
Erices R; Bravo ML; Gonzalez P; Oliva B; Racordon D; Garrido M; Ibañez C; Kato S; Brañes J; Pizarro J; Barriga MI; Barra A; Bravo E; Alonso C; Bustamente E; Cuello MA; Owen GI
Reprod Sci; 2013 Dec; 20(12):1433-46. PubMed ID: 23653391
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
13. In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel.
Casagrande N; Borghese C; Agostini F; Durante C; Mazzucato M; Colombatti A; Aldinucci D
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809553
[TBL] [Abstract][Full Text] [Related]
14. A Combination of Visudyne and a Lipid-anchored Liposomal Formulation of Benzoporphyrin Derivative Enhances Photodynamic Therapy Efficacy in a 3D Model for Ovarian Cancer.
Rizvi I; Nath S; Obaid G; Ruhi MK; Moore K; Bano S; Kessel D; Hasan T
Photochem Photobiol; 2019 Jan; 95(1):419-429. PubMed ID: 30499113
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Westfall SD; Skinner MK
Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic Priming Overcomes Per- and Polyfluoroalkyl Substance (PFAS)-Induced Platinum Resistance in Ovarian Cancer
Rickard BP; Tan X; Fenton SE; Rizvi I
Photochem Photobiol; 2023 Mar; 99(2):793-813. PubMed ID: 36148678
[TBL] [Abstract][Full Text] [Related]
18. Defining the therapeutic window of vertebral photodynamic therapy in a murine pre-clinical model of breast cancer metastasis using the photosensitizer BPD-MA (Verteporfin).
Akens MK; Hardisty MR; Wilson BC; Schwock J; Whyne CM; Burch S; Yee AJ
Breast Cancer Res Treat; 2010 Jan; 119(2):325-33. PubMed ID: 19263216
[TBL] [Abstract][Full Text] [Related]
19. Calculation of singlet oxygen dose using explicit and implicit dose metrics during benzoporphyrin derivative monoacid ring A (BPD-MA)-PDT in vitro and correlation with MLL cell survival.
Weston MA; Patterson MS
Photochem Photobiol; 2011; 87(5):1129-37. PubMed ID: 21575000
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
